Driving growth in a family-owned pharma company requires a balance of progress and preservation, writes Merz Therapeutics CEO ...

Fear of change is a key limiting factor that is slowing the adoption and value of AI across life sciences. It doesn't have to ...

Cuts to federal research funding at universities and research organizations are pushing academic scientists into life sciences entrepreneurship. Experts at Sidley offer tips for the transition.

BIO was as busy as ever in Boston this year. With more to come soon, here are a few initial thoughts on three events I attended.

Sometimes the key to making a breakthrough in research, in any field, is to look at the problem differently than anybody has ...

How To Be A Policy Advocate For Biotech With NewYorkBIO's Jennifer Hawks Bland On this week's episode of the Business of Biotech, Jennifer Hawks Bland, CEO of NewYorkBIO, shares insights on New York ...

In this series, we will monitor emerging policies and priorities from the new Trump administration and its agencies that are expected to have particular effects on healthcare and life science-related ...

Recently, there has been heightened focus on dual brand approaches in which the same molecule is approved for multiple indications and packaged, priced, and distributed under different brand names.

The number of psychedelic drug developers reaching Phase 2 and Phase 3 clinical trials is growing, in recognition of the level of unmet need in many mental health disorders and other conditions. Those ...

Smart money will find good ideas, and if you follow the money in biotech these days, that means looking to China. From January to mid-May 2025, Chinese biotechnology companies had announced licensing ...

By Arjan Singh Conferences and trade shows are great places to learn about your competitive environment, as most companies in the industry usually attend these events; this includes competitors, ...

In the world of biopharmaceutical innovation, groundbreaking scientific discoveries often do not directly translate into commercial success. Simply developing a promising therapeutic based on great ...